Amicus Therapeutics, Inc. (FOLD): Price and Financial Metrics

Amicus Therapeutics, Inc. (FOLD): $10.14

0.51 (-4.79%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add FOLD to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#88 of 351

in industry

FOLD Price/Volume Stats

Current price $10.14 52-week high $14.57
Prev. close $10.65 52-week low $9.02
Day low $10.13 Volume 1,671,900
Day high $10.57 Avg. volume 2,852,903
50-day MA $10.23 Dividend yield N/A
200-day MA $11.66 Market Cap 3.00B

FOLD Stock Price Chart Interactive Chart >


Amicus Therapeutics, Inc. (FOLD) Company Bio


Amicus Therapeutics is developing treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage disorders. The company was founded in 2002 and is based in Cranbury, New Jersey.


FOLD Latest News Stream


Event/Time News Detail
Loading, please wait...

FOLD Latest Social Stream


Loading social stream, please wait...

View Full FOLD Social Stream

Latest FOLD News From Around the Web

Below are the latest news stories about AMICUS THERAPEUTICS INC that investors may wish to consider to help them evaluate FOLD as an investment opportunity.

‘Time to Pull the Trigger,’ Says Morgan Stanley About These 2 Healthcare Stocks

It’s been a bountiful year for the stock market but that doesn’t mean there haven’t been laggards. The biotech industry, for example, has underperformed. While the Nasdaq Biotechnology Index (NBI) shows a 3% year-to-date gain, that is still some distance below the S&P 500’s 24% return. Therefore, with investor sentiment subdued, and some SMID-cap biotech firms still needing to raise capital against a challenging capital markets backdrop, Morgan Stanley’s Jeffrey Hung says the setup for SMID-cap

Yahoo | December 24, 2023

Amicus Therapeutics Inc's Chief Development Officer Sells Shares

On December 20, 2023, Jeff Castelli, Chief Development Officer of Amicus Therapeutics Inc (NASDAQ:FOLD), sold 19,154 shares of the company, according to a recent SEC Filing.

Yahoo | December 21, 2023

Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 8, 2023

BIO names longtime Amicus head John Crowley as new CEO

Crowley, a rare disease advocate who led Amicus for nearly two decades, will take the reins as the industry group seeks to challenge Medicare’s new drug pricing powers.

Yahoo | December 5, 2023

Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO

Crowley to Step Down from Amicus Board of Directors in March 2024 and Become Amicus Chairman Emeritus Michael Raab, Current Lead Independent Director, to Become Chairman of Amicus Board of Directors PRINCETON, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Executive Chairman of Amicus Therapeutics, will step down from the Amicus Board of Directors and assume the role of President and Chief Executive Officer of BIO, the Biotechnolo

Yahoo | December 5, 2023

Read More 'FOLD' Stories Here

FOLD Price Returns

1-mo 6.74%
3-mo -11.67%
6-mo -19.91%
1-year -22.54%
3-year 0.50%
5-year -15.92%
YTD -28.54%
2023 16.22%
2022 5.71%
2021 -49.98%
2020 137.06%
2019 1.67%

Continue Researching FOLD

Here are a few links from around the web to help you further your research on Amicus Therapeutics Inc's stock as an investment opportunity:

Amicus Therapeutics Inc (FOLD) Stock Price | Nasdaq
Amicus Therapeutics Inc (FOLD) Stock Quote, History and News - Yahoo Finance
Amicus Therapeutics Inc (FOLD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!